Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye diseases
Pharma
Apellis stock price slid 10% despite 'robust' growth of Syfovre
Despite the expansion of Syfovre in geographic atrophy ahead of analysts' expectations, Apellis' stock price has dropped 30% so far this year.
Angus Liu
May 8, 2024 11:30am
Appeals court backs Regeneron's antitrust suit against Novartis
Mar 19, 2024 10:40am
Novartis pawns off Indian ophthalmology brands to J.B. Pharma
Dec 20, 2023 10:01am
AstraZeneca, Takeda, BioNTech—Fierce Pharma Asia
Nov 10, 2023 8:05am
Apellis counters Izervay results with long-term data of its own
Nov 6, 2023 3:53pm
J&J snaps up photographer for vision health campaign
Oct 2, 2023 11:05am